Astrazeneca Plc (AZN), ASTRAZENECA PLC O (AZNCF) – AstraZeneca Imfinzi Combo Scores FDA Approval As First Immunotherapy Regimen For Biliary Tract Cancer
[ad_1] The FDA approved AstraZeneca plc’s AZN Imfinzi (durvalumab) for locally advanced or metastatic biliary tract cancer (BTC) in combination with chemotherapy (gemcitabine plus cisplatin). The approval was based on the…